Dual CDK4/6-PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcoma.
Barghi F, Saadatzadeh MR, Dobrota EA, Shannon HE, Bailey BJ, Young C, Malko R, Justice R, Riyahi N, Davis C, Bijangi-Vishehsaraei K, Kreklau K, Stevens LK, Koenig J, Sulayman S, Liu S, Wan J, Trowbridge MA, Coy K, Kennedy FM, Sinn AL, Just M, Jackson KW, Sandusky G, Wurtz LD, Collier CD, Mitchell D, Seiden EE, Greenfield EM, Doud E, Mosley A, Angus SP, Ferguson MJ, Pandya PH, Pollok KE.
Barghi F, et al.
Neoplasia. 2026 Feb;72:101266. doi: 10.1016/j.neo.2025.101266. Epub 2026 Jan 15.
Neoplasia. 2026.
PMID: 41544376
Free PMC article.